Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05814549 · ClinicalTrials.gov registry record
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
A clinical trial of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 9
- Enrollment target
- 7
- Study locations
NCT05814549: Active study of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05814549 is a study of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 189-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05814549, a study of Oropharyngeal Cancer and HPV Positive Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 9 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test to test for HPV DNA will help detect HPV-related Oropharyngeal Cancer/OPC.
Primary Outcome
: The primary objective is to determine the feasibility of screening by estimating the yield (proportion of subjects found to have HPV-related OPC out of all subjects screened).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST NavDx
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2031-03-31 |
What the registry record for NCT05814549 still lists
NCT05814549 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 189-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which NavDx is the first listed.
NCT05814549 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05814549 about?
NCT05814549 is a clinical study titled "A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)". The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test...
What is the current status of trial NCT05814549?
This trial is currently active not recruiting. The enrollment target is 9 participants. The study started on 2023-03-31. Estimated completion is 2031-03-31.
What conditions does trial NCT05814549 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma.
What interventions are being tested in trial NCT05814549?
The interventions under investigation include: NavDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05814549?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05814549 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05814549's enrollment target sits among peer trials
9 26th of 25 the lowest of 25 other Oropharyngeal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharyngeal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
RECRUITING
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
Liposomal Bupivacaine and Transoral Robotic Surgery
RECRUITING
-
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI